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| INTRODUCTION
Squamous cell carcinoma of the larynx is common in North America. 1 Organ preservation with chemoradiotherapy represents standard-of-care for locally advanced disease. 2, 3 Conventional techniques deliver 70 Gy over 7 weeks with incidental coverage of uninvolved larynx and healthy bystander tissues. Long-term outcomes from RTOG 91-11 demonstrated comparable larynx preservation and overall survival with sequential or concurrent chemoradiotherapy. 4 A discouraging finding from this trial was that improved organ preservation with concurrent chemoradiotherapy came at the cost of late deaths, potentially due to undetected toxicity. Since this trial, no significant advances have been made in radiation-based organ preservation strategies for advanced larynx cancer.
Accelerated hypofractionated irradiation of early-stage larynx cancer originated in Europe, with early results mirroring those achieved with conventional therapy. 5, 6 Despite conventional radiation techniques, there was no difference in cure rates when reducing radiation therapy from a 5-week course down to 3 weeks. 7 Later, a British Institute of Radiology study showed equivalent survival rates and no significant differences in toxicity with either a 3-week or 6-week radiation course. 6 More recently, the Royal Marsden Hospital treated 200 patients with T1 glottic cancer to a dose of 50-52.5 Gy in 16 daily fractions, 5 matching outcomes from historical studies. Beyond patient convenience and cost-saving advantages, hypofractionated radiation therapy may improve local control rates. 8 A phase III clinical trial showed improved local control with 56.25 Gy in 25 fractions compared to 60-66 Gy in 30-33 fractions, with equivalent toxicity. 9 We have initiated a multi-institutional phase I trial of 5-fraction stereotactic body radiotherapy (SBRT) for Stage III-IVa laryngeal cancer. SBRT divides intended radiation dose into five or fewer fractions with steep dose gradients and tight treatment accuracy constraints.
Thus, SBRT employs dramatically higher daily doses than conventional therapy, and holds promise for improving outcomes for highrisk disease. For example, local control of early-stage lung cancer with conventional radiation treatment is less than 50%, while newer series employing SBRT demonstrate improved local control approximating 90%. [10] [11] [12] Current radiation delivery techniques are based on a planning CT scan acquired before therapy begins, without planned changes during treatment. Fig. 4 . Our system calculated an average daily PTV coverage deficiency of 1.5%, while the commercial system calculated an average PTV coverage deficiency of 3.1%.
Delivered PTV dose coverage for all study cases were quantified and compared with prescribed doses using an in-house Matlab program. The protocol required prescription dose cover 95% of PTV. Our patients came from two studies with different advanced stages of cancer. Advanced stage disease (Pt# 6-10) with larger GTV and disease spread outside the laryngeal cartilage indeed makes the balance between PTV coverage and OAR sparing more challenging to achieve. Figure 5 illustrates the PTV prescription dose coverage as a function of GTV volume and it shows that coverage decreases with GTV volume.
Changes in bystander dose delivery to organs at risk (OARs) are detailed in Table 4 . Maximum point dose and Dmean to arytenoids, spinal cord, and parotids were well respected in all cases. Cumulative
Dmax to a single carotid artery increased by 13.9 Gy (patient #3) and 6.5 Gy (patient #2) from intended doses in two patients. Dmax 
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